Heffter Research Institute
15
2
3
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
6.7%
1 terminated/withdrawn out of 15 trials
91.7%
+5.2% vs industry average
0%
0 trials in Phase 3/4
64%
7 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Role: collaborator
Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care
Role: collaborator
Psilocybin - Induced Neuroplasticity in the Treatment of Major Depressive Disorder
Role: collaborator
Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine
Role: collaborator
Visual Surround Suppression and Perceptual Expectation Under Psilocybin
Role: collaborator
Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study
Role: collaborator
Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety
Role: collaborator
Efficacy of Psilocybin in OCD: a Double-Blind, Placebo-Controlled Study.
Role: collaborator
PAPR: PAP + MBSR for Front-line Healthcare Provider COVID-19 Related Burnout
Role: collaborator
Psilocybin for the Treatment of Cluster Headache
Role: collaborator
Effects and Therapeutic Potential of Psilocybin in Alcohol Dependence
Role: collaborator
A Double-Blind Trial of Psilocybin-Assisted Treatment of Alcohol Dependence
Role: collaborator
Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors
Role: collaborator
Psychopharmacology of Psilocybin in Cancer Patients
Role: collaborator
Pharmacological Interaction Between Pindolol and MDMA (3,4-Methylenedioxymethamphetamine)
Role: collaborator
All 15 trials loaded